Gland Pharma Ltd shares slumped 9% on 7 August after the company announced its quarterly earnings for April-June. 

The company reported a 25.9% year-on-year decline in net profit to Rs 143.8 crore for the quarter under review from Rs 194 crore reported in the same quarter of the previous fiscal year. 

However, the revenue from operations of the company during the quarter stood at Rs 1,401.7 crore, marking a 16% YoY increase from Rs 1,208.7 crore reported in the same quarter last year. 

On the operating front, the earnings before interest, tax, depreciation, and amortisation (EBITDA) slumped by 10% YoY to Rs 264.4 crore during the quarter compared to Rs 293.9 crore recorded in Q1FY24. The EBITDA margin contracted to 19% in Q1FY25 against 24.3% in Q1FY24. 

Srinivas Sadu, executive chairman and CEO of Gland Pharma, said, “We reached Rs 14,017 million in total revenue, a 16% increase from Q1FY24. The growth aligns with our projections and is primarily driven by the US market, which saw a 27% revenue increase led by existing and certain new products.” 

Srinivas added, “Our base business Ebitda margins were at 29%, and consolidated Ebitda margins for the quarter were 19%, mainly affected by Cenexi. We’re confident in our ability to meet our fiscal year goals and are excited about the growing opportunities and even stronger results expected in the coming quarters.”

At 1:41 pm, the shares of Gland Pharma were trading 4.72% lower at Rs 2,007.60 on NSE.

Tired of missing hot stocks? Unicorn Signals provides powerful tools like stock scans and more help you make informed trading decisions. Download now and take control of your portfolio!